BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9120902)

  • 1. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
    Small EJ; Baron AD; Fippin L; Apodaca D
    J Urol; 1997 Apr; 157(4):1204-7. PubMed ID: 9120902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
    Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
    J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
    Herrada J; Dieringer P; Logothetis CJ
    J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
    Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
    Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
    Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
    J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
    Ryan CJ; Weinberg V; Rosenberg J; Fong L; Lin A; Kim J; Small EJ
    J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
    BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
    Nakabayashi M; Xie W; Regan MM; Jackman DM; Kantoff PW; Oh WK
    Cancer; 2006 Sep; 107(5):975-81. PubMed ID: 16862573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.
    Small EJ; Baron A; Bok R
    Cancer; 1997 Nov; 80(9):1755-9. PubMed ID: 9351544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer.
    Wilkinson S; Chodak G
    Eur Urol; 2004 May; 45(5):581-4; discussion 585. PubMed ID: 15082199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
    Small EJ; Halabi S; Dawson NA; Stadler WM; Rini BI; Picus J; Gable P; Torti FM; Kaplan E; Vogelzang NJ
    J Clin Oncol; 2004 Mar; 22(6):1025-33. PubMed ID: 15020604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
    Eklund J; Kozloff M; Vlamakis J; Starr A; Mariott M; Gallot L; Jovanovic B; Schilder L; Robin E; Pins M; Bergan RC
    Cancer; 2006 Jun; 106(11):2459-65. PubMed ID: 16615097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
    Ryan CJ; Halabi S; Ou SS; Vogelzang NJ; Kantoff P; Small EJ
    Clin Cancer Res; 2007 Apr; 13(7):2030-7. PubMed ID: 17404083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.
    Scholz M; Jennrich R; Strum S; Brosman S; Johnson H; Lam R
    J Urol; 2005 Jun; 173(6):1947-52. PubMed ID: 15879788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
    Kassouf W; Tanguay S; Aprikian AG
    J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
    Figg WD; Liu Y; Arlen P; Gulley J; Steinberg SM; Liewehr DJ; Cox MC; Zhai S; Cremers S; Parr A; Yang X; Chen CC; Jones E; Dahut WL
    J Urol; 2005 Mar; 173(3):790-6. PubMed ID: 15711271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.